Modulatory effects of Antibody replacement therapy to innate and Adaptive immune cells
Modulatory effects of Antibody replacement therapy to innate and Adaptive immune cells
复制标题
DOI：
10.3389/fimmu.2017.00697
复制
发表时间：
2017-06-16
影响因子：
7.3
通讯作者：
Mitrevski, Milica
中科院分区：
文献类型：
--
作者：
Quinti, Isabella;Mitrevski, Milica
以替代剂量给予的静脉注射免疫球蛋白以与使用高剂量时或通过体外实验条件分析其作用时观察到的不同方式调节一抗缺乏症（PAD）中的先天性和适应性免疫细胞。这种作用似乎对先天性细胞有益，因为树突状细胞成熟，促炎单核细胞减少，中性粒细胞功能得以保留。对适应性免疫细胞的影响不太清楚。IVIg诱导Treg的短暂增加和CD4细胞的长期增加。更复杂和更少了解的是IVIg与PAD患者缺陷B细胞的相互作用。缺乏数据的基础上，需要更多的研究与PAD患者在得出结论的基础上，在体外研究IVIg的体内作用机制。
Intravenous immunoglobulin administered at replacement dosages modulates innate and adaptive immune cells in primary antibody deficiencies (PAD) in a different manner to what observed when high dosages are used or when their effect is analyzed by in vitro experimental conditions. The effects seem to be beneficial on innate cells in that dendritic cells maturate, pro-inflammatory monocytes decrease, and neutrophil function is preserved. The effects are less clear on adaptive immune cells. IVIg induced a transient increase of Treg and a long-term increase of CD4 cells. More complex and less understood is the interplay of IVIg with defective B cells of PAD patients. The paucity of data underlies the need of more studies on patients with PAD before drawing conclusions on the in vivo mechanisms of action of IVIg based on in vitro investigations.